Aurinia Pharmaceuticals (AUPH) Interest & Investment Income (2020 - 2026)

Aurinia Pharmaceuticals has reported Interest & Investment Income for 7 years, with the latest figure at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 1.51% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.5 million (down 15.57% YoY), and the FY2025 full-year result was $13.6 million, down 20.02% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $3.5 million, roughly flat from $3.5 million in the prior quarter.
• The five-year high for Interest & Investment Income was $4.6 million in Q4 2023, with the low at $262000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $3.3 million across 5 years, with a median of $3.6 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income soared 2568.81% — and 2025, when it decreased 23.85%.
• Aurinia Pharmaceuticals' Interest & Investment Income stood at $2.9 million in 2022, then surged by 57.03% to $4.6 million in 2023, then fell by 12.7% to $4.0 million in 2024, then slipped by 12.29% to $3.5 million in 2025, then climbed by 0.49% to $3.5 million in 2026.
• The last three Interest & Investment Income figures came in at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.